LET003

LET003 is a preclinical-stage monoclonal antibody being developed by Harbour BioMed (HBM Holdings) for the treatment of obesity. As part of the company's metabolic disease pipeline, LET003 is designed to address weight management and metabolic health, although its specific molecular target and exact mechanism of action remain undisclosed by the developer. It represents a biologic approach to obesity, distinct from the company's other metabolic candidate, LET001, which utilizes LYTAC (Lysosome Targeting Chimera) technology. The program leverages Harbour BioMed's antibody discovery platforms to identify and target novel pathways involved in metabolic regulation.